Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of KarXT in Schizophrenia
NCT04659174Phase 3Completed
- Sponsor
- Karuna Therapeutics
- Start
- Feb 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events up to 53 weeks. Started Feb 2021; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04659174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659174.